Skip to main content

Table 2 IC50 values of 13 targeted agents in 10 bladder cancer cell lines, with their molecular targets indicated

From: Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer

Drug Target HT1376 J82 RT4 T24 UMUC3 5637 SW780 253 J 253 JBV HT1197
Afatinib EGFR: HER2 NA 3.93 3.08 4.41 4.54 0.43 3.7 1.85 1.53 NA
Axitinib PDGFR: KIT: VEGFR 8.95 > 10 7.34 9.25 6.44 3.15 14.5 NA > 10 > 10
Caborazantinib MET: RET: VEGFR2 9.55 > 10 2.93 NA > 10 9.22 6.53 NA > 10 > 10
Erlotinib EGFR 5.62 NA 6.9 7.99 > 10 3.41 > 10 NA > 10 > 10
Everolimus mTOR 3.77 2 > 10 0.33 0.67 2.2 > 10 NA 1.5 0.71
GDC-0879 RAF NA NA NA NA NA NA NA NA > 10 NA
Lapatinib EGFR:ERBB2 2.73 5.12 0.57 6.82 2.49 1.66 1.45 NA 2.35 4.7
Lonafanib FNTB NA > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 NA
Nutlin-3 p53-MDM2 interaction NA NA NA NA NA NA > 10 NA > 10 > 10
Gefitinib AKT1:EGFR NA > 10 > 10 > 10 > 10 1.14 NA 3.11 3.8 NA
Trametinib MEK NA NA 2.54 NA NA NA > 10 > 10 NA NA
Vermurafenib BRAF > 10 > 10 NA NA > 10 > 10 > 10 NA > 10 > 10
Vorinostat HDAC inhibitors Class I, IIa, IIb, IV 2.48 2.95 1.52 0.9 2.35 1.2 1.36 NA 1.07 3.47
  1. The value represents IC50 (μM)